Orbis Medicines
Business Services · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Nordre Fasanvej 215, Frederiksberg, Capi...Website
www.orbismedicines.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Orbis Medicines
Orbis Medicines is a biotechnology company focused on oral macrocycle drug discovery. Orbis was founded in 2021.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orbis Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Orbis Medicines launches new products
Check if Orbis Medicines has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Orbis Medicines has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Orbis Medicines is spiking on competitors!
Earning: See what the market has to say on Orbis Medicines recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Orbis Medicines had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Orbis Medicines
Orbis Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Orbis Medicines is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Orbis Medicines is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Orbis Medicines.
Orbis Medicines financials insights
Gather financial insights about Orbis Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$92.3M
Orbis Medicines Tech Stack
A closer look at the technologies used by Orbis Medicines
Orbis Medicines News & Media
Orbis Medicines Names Veteran R&D Leader Mikael Dolsten Board Chair
COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific Officer, President, Pfizer Research & Development, as Chairperson of the Board of Directors. In more than 15 years at Pfizer, Dr. Dolsten oversaw the development and approval of more than 35 therapies and vaccines, and moved more than 100 drug candidates into clinical development. “Mikael has a long and sucOrbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles
COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the close of a EUR 90 million Series A funding round, bringing the total amount raised by the company to EUR 116 million. The funds will support the development of Orbis’ pipeline of next-generation oral macrocycle drugs, called ‘nCycles.’ This financing was led by NEA (New Enterprise Associates) with participation from new investors including Eli Lilly and Company, Cormorant, theNovo Holdings Participates in €90 Million Series A Financing Round for Orbis Medicines to Support Development of Oral Macrocycle Drugs
Financing to support the development of Orbis' pipeline of next-generation macrocycles, nCycles, with an initial focus on validated blockbuster biologic targets Orbis' nGen platform systematically explores oral macrocycle design with automated chemistry and machine learning Novo Holdings...Orbis Medicines to Expand With New R&D Site in Copenhagen
COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines to expand with new R&D site in Copenhagen to support acceleration of portfolio of first-in-class oral macrocycle drugs.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orbis Medicines
Sign Up For FreeTo access detailed company insights
Orbis Medicines is a biotechnology company focused on oral macrocycle drug discovery. Orbis was founded in 2021.... Read More
